Review Article

Pharmacological Strategies to Prevent Contrast-Induced Acute Kidney Injury

Pattharawin Pattharanitima and Adis Tasanarong

Nephrology Unit, Department of Medicine, Faculty of Medicine, Thammasat University (Rangsit Campus), Klong Luang, Pathumtani 12121, Thailand

Correspondence should be addressed to Adis Tasanarong; adis_tasanarong@hotmail.com

Received 19 October 2013; Revised 3 January 2014; Accepted 7 January 2014; Published 26 February 2014

Academic Editor: Michele Andreucci

Copyright © 2014 P. Pattharanitima and A. Tasanarong. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Contrast-induced acute kidney injury (CI-AKI) is the most common iatrogenic cause of acute kidney injury after intravenous contrast media administration. In general, the incidence of CI-AKI is low in patients with normal renal function. However, the rate is remarkably elevated in patients with preexisting chronic kidney disease, diabetes mellitus, old age, high volume of contrast agent, congestive heart failure, hypotension, anemia, use of nephrotoxic drug, and volume depletion. Consequently, CI-AKI particularly in high risk patients contributes to extended hospitalizations and increases long-term morbidity and mortality. The pathogenesis of CI-AKI involves at least three mechanisms; contrast agents induce renal vasoconstriction, increase oxygen free radicals through oxidative stress, and direct tubular toxicity. Several strategies to prevent CI-AKI have been evaluated in experimental studies and clinical trials. At present, intravascular volume expansion with either isotonic saline or sodium bicarbonate solutions has provided more consistent positive results and was recommended in the prevention of CI-AKI. However, the proportion of patients with risk still develops CI-AKI. This review critically evaluated the current evidence for pharmacological strategies to prevent CI-AKI in patients with a risk of developing CI-AKI.

1. Introduction

Contrast-induced acute kidney injury (CI-AKI) is the most common iatrogenic cause of acute kidney injury (AKI) after intravenous contrast media administration, with an incidence occurring from 1 to 25% [1–4]. CI-AKI has been defined as the acute deterioration of renal function after contrast media administration in the absence of other causes [5]. Unfortunately, the definition of CI-AKI has not been reliable in the literature, which makes the data comparison from various complex studies. In general, CI-AKI was defined as an increase in serum creatinine (SCr) concentration of 0.5 mg/dL or 25% above baseline within 48 h after contrast administration [6–10]. Impairment of renal function in CI-AKI occurs within 3 days after intravenous contrast media administration, while the peak of SCr is observed at 3 to 5 days and returns to the baseline value within 1 to 3 weeks [11, 12]. The incidence of CI-AKI is low (1 to 2%) in patients with normal renal function [1] but increases as high as 25% in high risk patients especially with chronic kidney disease (CKD) or diabetes mellitus with CKD [2, 13]. In addition, old age, higher volume of contrast agent used, congestive heart failure, hypotension, anemia, use of nephrotoxic drug, and volume depletion have been associated with increased risk of CI-AKI [14–16]. Consequently, CI-AKI, particularly in high risk patients, contributes to extended hospitalizations and increases long-term morbidity and mortality [17–19].

Development of CI-AKI involves at least three complementary pathophysiological processes. First, contrast agents induce renal vasoconstriction, accompanied by shunting of blood flow from the medulla to the cortex, a consequence of reducing renal blood flow to the medulla which is followed by renal medulla ischemia [20]. Second, hypoxia can promote further ischemic renal injury by the increase of oxygen free radicals through oxidative stress [21]. Organ injury occurs when tissue hypoperfusion generates reactive oxygen species (ROS) that exceed the patient’s antioxidant reserves [22]. Finally, contrast agent is direct tubular toxicity, leading to
mitochondrial dysfunction, generation of ROS, and program
cell death [6, 22, 23].

In fact, there is no effective therapy once AKI has
turned on. Thus, preventive approach should be the best
option for all patients with risk to avoid CI-AKI. Several
strategies to prevent CI-AKI have been tested in animal
models and clinical trials. The rationale for the prevention
of CI-AKI by periprocedural intravascular volume expansion is
through blocking its two complementary pathophysiological
processes [24]. First, expansion of the intravascular space is
thought to blunt the vasoconstrictive effect of contrast on
the renal medulla. Second, intravascular fluids are believed to
attenuate the direct toxic effect of contrast agents on tubular
epithelial cells. Hence, intravascular volume expansion with
isotonic saline and using of iso-osmolar contrast agents
have provided more consistent positive results and were
recommended in the prevention of CI-AKI [25, 26]. However,
the proportion of patients with risk still develops CI-AKI.

Several pharmacologic agents have been evaluated for the
prevention of CI-AKI. The mechanisms of pharmacological
prophylaxis for CI-AKI include vasodilator; antioxidant
agents have been implicated in the pathogenesis of CI-AKI.
This review discusses the current pharmacological strategies
to prevent CI-AKI in patients with the risk of developing CI-
AKI.

2. Pharmacological Strategies to
Prevent CI-AKI

2.1. Intravascular Volume Expansion for CI-AKI Prevention.
The intravascular volume expansion was believed to pre-
vent the adverse effect of contrast media administration
by 2 distinct mechanisms: (1) reducing the vasoconstrictive
effect of contrast media on renal medulla by suppression of
vasopressin secretion, inhibition of renin-angiotensin-
aldosterone system, and increase of prostaglandin synthesis,
and (2) attenuating the direct toxic effect of contrast media on
renal tubular epithelial cells by decreasing proximal tubular
salt and water reabsorption which results in diluting the
intratubular fluid and reducing the intratubular viscosity
[24]. In animal model, the sodium-replete dogs had less
magnitude and duration of vasoconstrictive response after
contrast media administration than sodium-deplete dogs
[27]. A reduction of glomerular filtration rate, renal plasma
flow, and alteration of the antioxidant enzyme activity
after contrast media administration occurred only in water-
depleted rats but not in water-replete rats [28, 29].

The first clinical trial for intravascular volume expansion
to prevent CI-AKI was presented in 1994. Solomon et al. [30]
randomized 78 patients with CKD who underwent coronary
angiography to receive intravenous 0.45% saline alone, for
12 h before and 12 h after the procedure, or in a combination
with mannitol or furosemide. The incidence of CI-AKI
occurred 11% in 0.45% saline group, 28% in 0.45% saline plus
mannitol group, and 40% in 0.45% saline plus furosemide
group ($P = 0.02$ for the comparison with the 0.45%
saline group). However, the efficacy of intravenous volume
expansion to prevent CI-AKI was inconclusive because there
was no control or nonsaline infusion group in this study. In
addition, the most suitable route of fluid administration and
the type of fluid was doubtful.

2.2. Oral Fluid versus Intravenous Fluid for CI-AKI Prophylaxis.
There are several trials studied on the effects of route of
fluid administration on CI-AKI prophylaxis. Taylor et al. [31]
randomized 36 patients with CKD who underwent cardiac
catheterization to receive intravenous 0.45% saline at a rate of
75 mL/h for 12 h before and 12 h after the procedure or oral
hydration at a rate of 1,000 mL over 10 h before the procedure
plus intravenous 0.45% saline at a rate of 300 mL/h beginning
just before and 6 h after the procedure. The incidences of
CI-AKI were not different between intravenous alone and
intravenous plus oral fluid group, 6 and 11%, respectively.
Trivedi et al. [32] randomized the patients who underwent
nonemergency cardiac catheterization to receive intravenous
0.9% saline at a rate of 1 mL/kg/h for 12 h before and 12 h after
the procedure or unrestricted oral fluid. The incidences of
CI-AKI were significantly higher in intravenous fluid group than
in unrestricted oral fluid group, 3.7 and 34.6%, respectively
($P = 0.005$). Dussol et al. [33] randomized 312 patients
with CKD who underwent various radiological procedures
which required contrast media into 4 groups to receive (1)
oral NaCl 1g per 10 Kg for 2 days before the procedure,
(2) intravenous 0.9% saline at a rate of 15 mL/kg/h for 6 h
before the procedure, (3) intravenous 0.9% saline at a rate
of 15 mL/kg/h for 6 h before the procedure plus theophylline
5 mg/kg 1h before the procedure, or (4) intravenous 0.9%
saline at a rate of 15 mL/kg/h for 6 h before the procedure
plus furosemide 3 mg/kg after the procedure. The incidences
of CI-AKI were not significantly different between the 4
groups: 6.6, 5.2, 7.5, and 15.2% in groups 1 to 4, respectively.
Cho et al. [34] randomized 91 patients with CKD who
underwent cardiac catheterization into 4 groups to receive
(1) intravenous 0.9% saline 3 mL/kg over 1 h just before and
at a rate of 1 mL/kg/h for 6 h after the procedure, (2)
intravenous isotonic NaHCO$_3$ 3 mL/kg over 1 h just before
and at a rate of 1 mL/kg/h for 6 h after the procedure, (3) oral
water 500 mL in 2 h which begin 4 h before and 600 mL after
the procedure, (4) oral water 500 mL in 2 h which begin 4 h
before the procedure with oral NaHCO$_3$ 46.4 mEq 20 min
before the procedure, and (5) 600 mL of oral water after
the procedure with oral NaHCO$_3$ 30.4 mEq at 2 and 4 h
after the initial dose. The incidences of CI-AKI were not
significantly different between the 4 groups: 22, 10, 5, and 5%
in groups 1 to 4, respectively. According to these conflicting
results, the appropriate route of fluid administration remains
inconclusive.

2.3. Isotonic Fluid versus Hypotonic Fluid for CI-AKI Prophylaxis.
Mueller et al. [25] conducted a study to compare the
efficacy of intravenous 0.45% NaCl and 0.9% NaCl for
CI-AKI prophylaxis. 1,620 patients who underwent coronary
angiography were randomized to receive 0.9% saline or 0.45%
saline plus 5% glucose at a rate of 1 mL/kg/h beginning
at 8 AM on the day of procedure until 8 AM on the next
morning. The incidences of CI-AKI were significantly lower
in isotonic saline group than in half-isotonic saline group: 0.7 and 2.0%, respectively ($P = 0.04$). On subgroup analysis, the patients with diabetes received radiocontrast ≥ 250 mL and particularly female patients had benefit from the isotonic fluid therapy.

2.4. Sodium Chloride versus Sodium Bicarbonate for CI-AKI Prophylaxis. The administration of intravenous fluid that contains sodium bicarbonate can cause an alkalinization of the intratubular fluid and result in reduction of injurious hydroxyl radicals, which, theoretically, might be more beneficial than sodium chloride fluid therapy in CI-AKI prophylaxis. Merten et al. [35] randomized 119 patients with SCR ≥ 1.1 mg/dL who underwent radiographic procedure requiring contrast media to receive isotonic saline or sodium bicarbonate at a similar rate of 3 mL/kg/h for 1 h before and 1 mL/kg/h for 6 h after the procedure. The incidences of CI-AKI were significantly higher in sodium chloride group than in sodium bicarbonate group: 13.6 and 1.7%, respectively ($P = 0.02$). Briguori et al. randomized 366 patients with CKD who underwent coronary and/or peripheral angiography into 3 groups to receive intravenous (1) 0.9% saline with NAC, (2) sodium bicarbonate with NAC, and (3) 0.9% saline with ascorbic acid and NAC. The incidences of CI-AKI were significantly lower in sodium bicarbonate with NAC group: 9.9, 1.9, and 10.3% in groups 1 to 3, respectively ($P = 0.019$). Recio-Mayoral et al. [36] randomized 111 patients with acute coronary syndrome who underwent emergency percutaneous coronary intervention to receive sodium bicarbonate with NAC or 0.9% saline with NAC. The incidences of CI-AKI were significantly lower in sodium bicarbonate with NAC than in 0.9% saline with NAC group: 1.8 and 21.8%, respectively ($P < 0.001$).

2.5. Meta-Analysis Comparing the Efficacy of Sodium Chloride with Sodium Bicarbonate for CI-AKI Prophylaxis. Data from several meta-analyses of the efficacy of sodium chloride versus sodium bicarbonate for CI-AKI prophylaxis are summarized in Table 1. Six out of six meta-analyses [37–42] demonstrated that volume expansion therapy with sodium bicarbonate is superior to sodium chloride in preventing CI-AKI. However, the efficacy of sodium bicarbonate and sodium chloride was not significantly different in meta-analyses from 14 unpublished studies by Zoungas et al. [41] (RR = 0.78, 95% confidence interval 0.52–1.17; $P = 0.05$). The inconsistent data between published and unpublished studies should be cautiously considered in the use of this treatment for CI-AKI prophylaxis until more reliable evidence from large-scale clinical studies is available.

In summary, although the most efficacious route for volume expansion in CI-AKI prophylaxis remains debatable, the intravenous route is more reliable for fluid delivery to the patients. Thus, we suggested using the intravenous route if it is available for CI-AKI prophylaxis. The CI-AKI prevention with isotonic saline is more effective than hypotonic saline. And according to the available data, the volume expansion with saline is at least as effective as sodium bicarbonate for CI-AKI prophylaxis. Thus, we suggested using intravenous/isotonic saline or sodium bicarbonate for volume expansion in CI-AKI prophylaxis depending on the patient’s condition.

2.6. N-Acetylcysteine (NAC) for CI-AKI Prevention. The possible role of reactive oxygen radicals in the pathogenesis of CI-AKI led to the evaluation of NAC as an antioxidant. The antioxidant effect of NAC relates to both direct free radical scavenging activity and capability to enhance glutathione synthesis [43]. In experimental study, the administration of contrast media results in augmentation of lipid peroxidation marker, reduction of glomerular filtration rate (GFR), and deterioration of tubular structures. In contrast, pretreatment of animals with antioxidants diminishes the hazardous effect of contrast media, including NAC that attenuates the adverse renal effect from contrast media [28, 44–46].

The clinical trials comparing NAC and placebo for prophylaxis of CI-AKI after angiography are shown in Table 2. The first clinical trial for NAC in the prevention of CI-AKI was reported by Tepel et al. [47] in 2000. In this prospective study, 83 patients with CKD who underwent computed tomography (CT) with intravenous contrast media were randomized to receive 600 mg of oral NAC or placebo twice daily for 2 days. All patients received intravenous 0.45% NaCl at a rate of 1 mL/kgBW/h for 12 h before and 12 h after administration of the contrast media. The CI-AKI occurred in 2% of the NAC group compared to 21% in the placebo group ($P = 0.01$). In 2002, Shyu et al. [48] prospectively randomized 121 patients with CKD who underwent a coronary procedure with standard intravascular volume expansion protocol to receive oral NAC or placebo. The CI-AKI occurred in 3.3% in the NAC group, and 24.6% in placebo group ($P < 0.001$). Similarly, the prospective study published by Kay et al. [49] in 2005 demonstrated a significantly lower incidence of CI-AKI in the patients with CKD undergoing elective coronary intervention who receive oral NAC (4%), compared to the placebo group (12%) ($P = 0.03$).

In contrast, several studies failed to demonstrate the benefit of NAC in the prevention of CI-AKI. Webb et al. [50] prospectively randomized 487 CKD patients who underwent cardiac catheterization to receive a single dose of intravenous NAC 500 mg or placebo within 1 h before the administration of contrast media. All patients received 200 mL of intravenous 0.9% NaCl before the procedure, followed by 1.5 mL/kgBW/h for 6 h or until discharge. The incidences of CI-AKI in both groups were similar: 23.3% and 20.7% in NAC and placebo groups, respectively ($P = 0.57$). In 2011, the largest trial of NAC for the prevention of CI-AKI was published by ACT investigators [3]. The 2,308 patients with one or more risk factors for CI-AKI undergoing coronary or peripheral arterial angiography were randomized to receive 4 doses of 600 mg oral NAC or placebo twice daily. All patients received 0.9% NaCl at a rate of 1 mL/kgBW/h from 6 to 12 h before and 6 to 12 h after procedure. The incidences of CI-AKI were similar, 12.7% in both groups ($P = 1.00$).

2.7. Systematic Review and Meta-Analysis of the Efficacy of NAC for CI-AKI Prophylaxis. Data from several meta-analyses of the efficacy of NAC for CI-AKI prophylaxis are...
summarized in Table 3. To date, at least nine out of the 16 meta-analyses have showed beneficial of NAC treatment effect in reducing the incidence of CI-AKI compared to placebo [51–59]. However, disparate results are shown in the remaining studies [3, 60–65]. Various factors may contribute to these inconsistent efficacies of NAC in CI-AKI prophylaxis, including definition of CI-AKI, baseline risk factors, timing and route of NAC administration, dosage of NAC, amount and type of intravenous hydration protocols, volume, type, and route of administration of contrast media, type of performed procedures, and methodological characteristics of trials. In 2008, Kelly et al. [58] conducted a meta-analysis that included 41 studies with a sample size of 3,393 patients. Their results suggested that oral or IV NAC significantly lowered the risk of CI-AKI when compared with intravascular volume expansion with saline alone (relative risk (RR): 0.62, 95% CI: 0.44–0.88). In 2011, ACT investigators [3] encompassed 46 randomized controlled trials comparing NAC with placebo in patients undergoing cardiac or peripheral angiography. The investigators showed that NAC does not reduce the risk of CI-AKI or other clinically relevant outcomes in at risk patients (RR: 1.00, 95% CI: 0.81–1.25; P = 0.97).

In summary, the data regarding the efficacy of NAC in CI-AKI prophylaxis remain controversial. However, due to very low toxicity, low cost, and potential benefit of NAC, this medication remains commonly used for the prophylaxis of CI-AKI. We recommend the use of oral NAC at a dose of 600 mg twice daily on the day before and day of the procedure to patients at risk of CI-AKI.

| Authors            | Year | Number of patients | Number of trials | RR  | 95% CI Low  | 95% CI High | P value   |
|--------------------|------|--------------------|------------------|-----|-------------|-------------|-----------|
| Hogan et al. [38]  | 2008 | 1,307              | 7                | 0.37| 0.18        | 0.714       | 0.005     |
| Kanbay et al. [39] | 2009 | 2,448              | 17               | 0.54| 0.36        | 0.83        | ND        |
| Navaneethan et al. [40] | 2009 | 1,652              | 12               | 0.46| 0.26        | 0.82        | 0.008     |
| Zoungas et al. [41] | 2009 |                    |                  |     |             |             |           |
| (i) Published studies |     | 1,846              | 9                | 0.43| 0.25        | 0.75        | 0.02      |
| (ii) Unpublished studies |     | 1,717              | 14               | 0.78| 0.52        | 1.17        | 0.05      |
| Kunadian et al. [42] | 2011 | 1,734              | 7                | 0.33| 0.16        | 0.69        | 0.003     |
| Jang et al. [37]   | 2012 | 3,609              | 19               | 0.56| 0.36        | 0.86        | 0.008     |

2.8. Statins for CI-AKI Prevention. Statins also have the pleiotropic effect, as an anti-inflammatory effect and antioxidant, besides the main inhibitory effect on hydroxymethylglutaryl coenzyme A reductase. In vitro, statins exerted the production of heme oxygenase-1 protein, interfered with NADPH oxidase activity, diminished adhesion molecule expression, and reduced the free radical formation [66–68]. Pretreatment of rats with statin appeared to attenuate the SCr level elevation and lessened the unfavorable histological findings in ischemic reperfusion injury model [68, 69]. Moreover, statin could attenuate CI-AKI in rat model through modulation of oxidative stress and proinflammatory cytokines [70].

The clinical trials comparing efficacy of statins and placebo for prophylaxis of CI-AKI after contrast media administration are shown in Table 4. In 2004, Attallah et al. [71] retrospectively reviewed 1,002 medical records of the patients who started statin in hospital before the cardiac catheterization compared to those who were not administered statin. The baseline characteristics, SCr, GFR, amount of intravenous fluid, and contrast were similar in both groups. The postcatheterization SCr was significantly better in the statin group (P < 0.001). The percentages of patients with CI-AKI were 17.2 and 22.3% in the statin and no statin groups, respectively (P = 0.028). Khanal et al. [72] published their retrospective study of 29,409 patients undergoing percutaneous coronary intervention who received preprocedure statin and those who did not. The incidences of CI-AKI were 4.37 versus 5.93 (P < 0.0001), and those of nephropathy requiring dialysis were 0.32 versus 0.49 (P = 0.03) in the patients who received statin and those who did not. In 2009, Xinwei et al. [73] performed the prospective randomized study to test whether the dosage of statins affects the efficacy of CI-AKI prophylaxis. The 284 patients with acute coronary syndrome undergoing coronary angiography were randomized 1:1 ratio into simvastatin 20 mg or 80 mg group. All patients were hydrated with intravenous 0.9% NaCl at a rate of 1 mL/kgBW/h for 6 to 12 h before and 12 h after coronary angiography. The incidence of CI-AKI was significantly less in simvastatin 80 mg group compared to 20 mg group: 5.3 versus 15.7%, respectively. This study showed the importance of statins dosage in the efficacy to prevent CI-AKI.

The prospective, randomized, placebo-controlled trial for determining the efficacy of statins in CI-AKI prevention was performed by Jo et al. [74] in 2008. A total of 3,080 patients who underwent coronary catheterization were randomized to receive simvastatin 40 mg or placebo every 12 h for 2 days before the administration of contrast media. All patients were hydrated with intravenous 0.45% NaCl at a rate of 1 mL/kgBW/h for 6 to 12 h before and after the procedure. The incidences of CI-AKI in both groups were similar: 2.5 and 3.4% in simvastatin and placebo groups, respectively. Several studies were performed using other statin, atorvastatin, to evaluate effect on CI-AKI prophylaxis. These studies have
### Table 2: Prospective, randomized clinical trials comparing N-acetylcysteine with placebo for prophylaxis of contrast-induced AKI after angiography.

| Authors | Year | Inclusion criteria | Type of procedure and contrast media | Number of patients | Intervention versus control | Study protocol | Intravascular volume expansion protocol | CI-AKI definition | Incidence of CI-AKI | RR requirement | P value | Intervention versus control (%) |
|---------|------|-------------------|-------------------------------------|-------------------|-----------------------------|---------------|----------------------------------------|------------------|-------------------|---------------|----------|-------------------------------|
| Tepel et al. [47] 2000 | Cr >1.2 mg/dL or GFR <50 mL/min/1.73 m² | CECT Iopromide | 41 versus 42 | NAC 600 mg po bid | None | N/2 in 1 mL/kg/h 12 hours before and after | Cr ≥25% or Cr ≥0.5/2d | 2 versus 21 | 0.01 | 0 versus 0 |
| Shyu et al. [48] 2002 | Cr 2–6 mg/dL or GFR 40 mL/min/1.73 m² | CAG Iopamidol | 60 versus 61 | NAC 400 mg po bid | Placebo | 0.4% NaCl 1 mL/kg/h 12 hours before and after | Cr ≥0.5/2d | 3.3 versus 24.6 | <0.001 | ND |
| Kay et al. [49] 2003 | Cr >1.2 mg/dL or GFR <60 mL/min/1.73 m² | CAG Iopamidol | 102 versus 98 | NAC 600 mg po bid | Placebo | NSS 1 mL/kg/h 12 hours before and 6 hours after with liberal oral fluid | Cr ≥25% or Cr ≥0.5/2d | 4 versus 12 | 0.03 | ND |
| Baskurt et al. [110] 2009 | GFR 30–60 mL/min/1.73 m² | CAG Ioversol | 73 versus 72 | NAC 600 mg po bid | (1) None (2) NAC 600 mg and theophylline 200 mg po bid | NSS 1 mL/kg/h 12 hours before and after | Cr ≥0.5/2d | 9.6 versus 6.9 | 0.033 | 0 versus 0 |
| Boccalandro et al. [133] 2003 | GFR <50 mL/min/1.73 m² | CAG Iodixanol | 75 versus 106 | NAC 600 mg po bid | None | 0.4% NaCl 75 mL/h 12 hours before and after | Cr ≥0.5/2d | 13 versus 12 | 0.842 | ND |
| Webb et al. [50] 2004 | GFR <50 mL/min/1.73 m² | CAG Ioversol | 242 versus 245 | Single dose of NAC 500 mg in DSW 50 mL IV 1h before | DSW 50 mL | NSS 200 mL before and 1.5 mL/kg 6 hours after | GFR ≥5 mL/min/1.73 m² | 23.3 versus 20.7 | 0.51 | 20 versus 0 |
| Gomes et al. [134] 2005 | Cr >1.2 mg/dL | CAG Ioxaglate | 77 versus 79 | NAC 600 mg po bid 2 doses before and after | Placebo | NSS 1 mL/kg/h 12 hours before and after | Cr ≥0.5/2d | 10.4 versus 10.1 | 1.00 | 2.6 versus 0 |
| Ozcan et al. [135] 2007 | Cr 1.2–4 mg/dL | CAG Ioxaglate | 88 versus 88 | NAC 600 mg po bid with NSS 1 mL/kg/h 6 hours before and after | 1 mL/kg/h for 6 hours before and after | Isotonic NaHCO₃ IV | Cr ≥25% or Cr ≥0.5/2d | 12.5 versus 4.5 | 0.706 | 0 versus 1.1 versus 1.1 |
| ACT investigators [3] 2011 | At least 1 risk factor for CI-AKI (Age >70 years, Cr >1.5 mg/dL, DM, CHF, IV EF <0.45, hypotension) | CAG/PAG ND | 1,172 versus 1,136 | NAC 600 mg po bid | Placebo | NSS 1 mL/kg/h 6–12 hours before and after | Cr ≥25% or Cr ≥0.5/2d | 12.7 versus 12.7 | 0.97 | 2.2 versus 2.3 |

bid: twice daily; CAG: coronary angiography; CECT: contrast enhanced computed tomography; CI-AKI: contrast-induced acute kidney injury; CHF: congestive heart failure; Cr: creatinine; d: day; DM: diabetes mellitus; D5W: 5% dextrose solution; GFR: glomerular filtration rate; h: hour; IV: intravenous; kg: kilogram body weight; LVEF: left ventricular ejection fraction; mg: milligram; mL: milliliter; NAC: N-acetylcysteine; ND: no data; NSS: normal saline solution; N/2: 0.4% NaCl; PAG: peripheral angiography; po: per oral route; RRT: renal replacement therapy.
Table 3: Systematic review and meta-analysis comparing the efficacy of N-acetylcysteine and placebo for contrast-induced AKI prophylaxis.

| Authors                  | Year | Number of patients | Number of trials | RR  | 95% CI | P value |
|--------------------------|------|--------------------|------------------|-----|--------|---------|
| Birck et al. [51]        | 2003 | 805                | 7                | 0.435 | 0.215-0.879 | 0.02   |
| Isenbarger et al. [52]   | 2003 | 805                | 7                | 0.37  | 0.16-0.84  | ND     |
| Alonso et al. [53]       | 2004 | 885                | 8                | 0.41  | 0.22-0.79  | 0.007  |
| Bagshaw and Ghali [54]   | 2004 | 1,261              | 14               | 0.54  | 0.32-0.91  | 0.02   |
| Pannu et al. [55]        | 2004 | 1,776              | 15               | 0.65  | 0.43-1.0   | 0.049  |
| Duong et al. [56]        | 2005 | 1,584              | 14               | 0.57  | 0.37-0.84  | 0.01   |
| Liu et al. [57]          | 2005 | 1,028              | 9                | 0.43  | 0.24-0.75  | ND     |
| Kelly et al. [58]        | 2008 | 6,379              | 41               | 0.62  | 0.44-0.88  | ND     |
| Kwok et al. [59]         | 2013 | 15,976             | 7                | 0.65  | 0.48-0.88  | ND     |
| Kshirsagar et al. [60]   | 2004 | 1,538              | 16               | ND    | ND      | ND     |
| Mirsa et al. [61]        | 2004 | ND                 | 27               | ND    | ND      | ND     |
| Nallamothu et al. [62]   | 2004 | 2,195              | 21               | 0.73  | 0.52-1.0   | 0.08   |
| Zagler et al. [63]       | 2006 | 1,892              | 13               | 0.68  | 0.46-1.02  | 0.06   |
| Gonzales et al. [64]     | 2007 | 2,476              | 22               | 0.87  | 0.68-1.12  | 0.28   |
| ACT Investigators [3]     | 2011 | 1,000              | 5                | 1.05  | 0.73-1.53  | ND     |
| Sun et al. [65]          | 2013 | 1,916              | 10               | 0.68  | 0.46-1.02  | 0.06   |

95% CI: 95% confidence interval; ND: no available data; NS: nonsignificant; RR: relative risk.

produced conflicting results [75–78]. Recently, there were 2 randomized controlled trials to determine the efficacy of rosuvastatin in CI-AKI prevention. First, Han et al. [79] randomized 2,998 patients with type 2 DM and CKD who were undergoing coronary or peripheral angiography to receive rosuvastatin 10 mg for 2 days before and 3 days after intervention or standard of care. The incidences of CI-AKI were significantly different: 2.3 and 3.9% in rosuvastatin and control groups, respectively (\(P=0.01\)). Leoncini et al. [80] compared the incidence of CI-AKI in 504 patients with non-ST elevated acute coronary syndrome undergoing coronary angiogram who receive rosuvastatin or no statin treatment on the admission. The incidence of CI-AKI was significantly lower in rosuvastatin group than in control group: 6.7 and 15.1%, respectively (\(P=0.003\)).

2.9. Systematic Review and Meta-Analysis of the Efficacy of Statin for CI-AKI Prophylaxis. Zhang et al. [81] performed a meta-analysis of published randomized clinical trials to determine the efficacy of short-term administration of high-dose statin compared to placebo among patients undergoing catheterization in preventing CI-AKI. From 8 clinical trials including 1,423 patients, the study showed that high-dose statin treatment could decrease the incidence of CI-AKI (RR: 0.51, \(P=0.001\)). However, the subgroup analysis showed that the incidence of CI-AKI was not different in the patients with preexisting renal impairment (RR: 0.9, \(P=0.73\)). In contrast, the meta-analysis by Zhou et al. [82] including 5 trials with a total of 1,009 patients revealed that short-term, high-dose statin treatment lowered the incidence of AKI in patients with CKD stage 4 and stage 5 in 3 clinical trials, but not in patients with CKD stage 1 to stage 3 in 2 clinical trials. Zhang et al. [83] performed a systematic review and meta-analysis to determine the efficacy of long-term statin pretreatment to prevent the CI-AKI. Among 6 cohort studies, the chronic statin therapy pretreatment had a protective effect against CI-AKI. In contrast, from 6 randomized controlled trials with a total of 1,194 patients, the short-term, high-dose statin pretreatment had a nonsignificant protective effect against CI-AKI (RR 0.7, 95% CI: 0.48–1.02).

In summary, the current data regarding the efficacy of statins in CI-AKI prophylaxis are inconclusive. There is not enough evidence to support the use of statins in radiology patients. In the future, large well-designed studies are needed to address the efficacy of statins and their long-term clinical outcomes.

2.10. Ascorbic Acid (Vitamin C) for CI-AKI Prevention. Due to the antioxidant properties of ascorbic acid, the efficacy of ascorbic acid in the prevention of oxidative stress-associated diseases has been extensively studied. In animal model, vitamin C was able to attenuate the pathological process in the postschismic oxidative injuries and gentamicin and cisplatin induced nephrotoxicities [84–86]. In addition, ascorbic acid protected the kidney in CI-AKI rat model against oxidant stress by an antioxidant property [87].

The details of the clinical trials were summarized in Table 5. Spargi et al. [88] prospectively randomized 231 patients who were undergoing coronary angiography to receive oral ascorbic acid 3 g 2h before and 2 g in the night and in the morning after the procedure or placebo. All patients were hydrated with 0.9% NaCl at a rate of 50–125 mL/h from randomization to at least 6 h after the procedure. The incidences of CI-AKI were 9 and 20% in the ascorbic acid and placebo groups, respectively (\(P=0.02\)).

However, the prospective, randomized clinical trials by Boscheri et al. [89], Jo et al. [90], and Zhou and Chen [91] showed the negative results of ascorbic acid in preventing...
Table 4: Prospective, randomized clinical trials comparing efficacy of statins and placebo for contrast-induced AKI after angiography prophylaxis.

| Authors          | Year | Type of procedure and contrast media | Number of patients | Study protocol | Intravascular volume expansion and NAC protocol | CI-AKI definition | Mean GFR intervention versus control (mL/min/1.73 m²) | Incidence of CI-AKI intervention versus control (%) | RRT requirement intervention versus control (%) |
|------------------|------|-------------------------------------|--------------------|---------------|-----------------------------------------------|-------------------|-----------------------------------------------------|--------------------------------------------------|-----------------------------------------------|
| Xinwei et al. [73] 2009 | CAG Iodixanol | 115 versus 113 | Simvastatin 20 mg/d before and 20 mg after | NSS 1 mL/kg/h 6–12 hours before and 12 hours after | ↑Cr ≥ 25%/2 days or ↑Cr ≥ 0.5/2 days | 86.5 versus 93.6 | 15.7 versus 5.3 | <0.05 | ND |
| Patti et al. [77] 2011 | CAG Iobitridol | 120 versus 121 | Atorvastatin 80 mg 12 hours and 40 mg 2 hours before | NSS 1 mL/kg/h ≥ 12 hours after | ↑Cr ≥ 25%/1-2 days or ↑Cr ≥ 0.5/1-2 days | 79.8 versus 77.0 | 5 versus 13.2 | 0.046 | 0 versus 0.8 |
| Quintavalle et al. [78] 2012 | CAG Iodixanol | 202 versus 208 | Atorvastatin 80 mg 1 days before | Isotonic NaHCO₃ 3 mL/kg/h 1 hour and 1 mL/kg/h 6 hours NAC 1200 mg po bid | ↑Cr ≥ 25%/1 day or ↑Cr ≥ 0.5/1 day | 42 versus 43 | 4.5 versus 17.8 | 0.005 | ND |
| Jo et al. [74] 2008 | CAG Iodixanol | 124 versus 123 | Simvastatin 40 mg po q3h for 2 days | Placebo | ↑Cr ≥ 25%/2 days or ↑Cr ≥ 0.5/2 days | 53.46 versus 55.4 | 2.5 versus 3.4 | 1.0 | 0 versus 0.8 |
| *Ozhan et al. [75] 2010 | CAG ND | Total 130 | Atorvastatin | None | NAC | ND | ND | 2 patients versus 7 patients* | NS | ND |
| Toso et al. [76] 2010 | CAG Iodixanol | 152 versus 152 | Atorvastatin 80 mg/d 2 days before and after | Placebo | NSS 1 mL/kg/h 12 hours before and after NAC 1200 mg po bid | ↑Cr ≥ 0.5/5 days or ↑Cr ≥ 25%/5 days | 46 versus 46 | 9.7 versus 11.2 | NS | NS | 0 versus 0.7 |
| Han et al. [79] 2013 | CAG/PAG Iodixanol | 1498 versus 1500 | Rosuvastatin 10 mg/d 2 before and 3 days after | Placebo | N/2 1 mL/kg/h 12 hours before and after | ↑Cr ≥ 25%/3 days or ↑Cr ≥ 0.5/3 days | 74.16 versus 74.43 | 2.3 versus 3.9 | 0.01 | 0 versus 0.1 |
| Loocini et al. [80] 2013 | CAG Iodixanol | 252 versus 252 | Rosuvastatin 40 mg po on admission then 20 mg/d | None | N/2 1 mL/kg/h 12 hours before and 24 hours after NAC 1200 mg po bid | ↑Cr ≥ 25%/3 days or ↑Cr ≥ 0.5/3 days | 82.5 versus 82.6 | 6.7 versus 15.1 | 0.003 | 0 versus 0.1 |

*The incidences of CI-AKI data in each group are not available. Data is shown as the number of patients who develop CI-AKI.

bid: twice daily; CAG: coronary angiography; CI-AKI: contrast-induced acute kidney injury; Cr: creatinine; CysC: cystatin C; d: day; h: hour; IV: intravenous; kg: kilogram body weight; mg: milligram; mL: milliliter; NAC: N-acetylcysteine; ND: no data; NSS: normal saline solution; N/2: 0.45% NaCl; po: per oral route; PAG: peripheral angiography; q12h: every 12 hours; RRT: renal replacement therapy.
**Table 5:** Prospective, randomized clinical trials comparing efficacy of vitamin C with placebo and other agents for contrast-induced AKI after angiography prophylaxis.

| Authors          | Year | Type of procedure and contrast media | Number of patients | Study protocol | Intravascular volume expansion and NAC protocol | CI-AKI definition | Mean GFR Intervention versus control (mL/min/1.73 m²) | Incidence of CI-AKI Requirement | P value | RRT requirement Intervention versus control (%) |
|------------------|------|--------------------------------------|--------------------|----------------|-----------------------------------------------|------------------|-----------------------------------------------------|---------------------------------|---------|-----------------------------------------------|
| Spargias et al.  | 2004 | CAG LONICM or IONICM                 | 118 versus 113     | Ascorbic acid 3 g po 2 hours before and 2 g in the night and in the morning after | Placebo           | NSS 50–125 mL/h from randomization to 6 hours after | \( \uparrow \text{Cr} \geq 25\% /2 \text{days or } \uparrow \text{Cr} \geq 0.5/2 \text{days} \) | 61.1 versus 68.1 | 9 versus 20 | 0.02 ND                                      |
| Boscheri et al.  | 2007 | CAG ND                               | 74 versus 69       | Ascorbic acid 1g | Placebo                                       | ND               | ND                                                  | 6.8 versus 4.3 | NS | ND                                          |
| Jo et al. [90]   | 2009 | CAG Iodixanol                        | 106 versus 106     | Ascorbic acid po q12h 3 and 2 g before and 2 and 2 g after | NAC 1200 mg po bid 4 doses, begin 1st dose in the evening before | N/2 1 mL/kg/h 12 hours before and after | \( \uparrow \text{Cr} \geq 25\% /2 \text{days or } \uparrow \text{Cr} \geq 0.5/2 \text{days} \) | 53.7 versus 53.7 | 4.4 versus 1.2 | 0.370 2 versus 1 |
| Zhou and chen    | 2012 | CAG Unspecified                      | 74 versus 82       | Ascorbic acid 3 g IV before and 0.5 g po q12h for 3 days after | Placebo           | NSS 1 mL/kg/h 4 hours before and 12 hours after | \( \uparrow \text{Cr} \geq 25\% /2 \text{days or } \uparrow \text{Cr} \geq 0.5/2 \text{days} \) | 52.5 versus 53.2 | 6.3 versus 5.4 | 0.69 ND                                      |
| Brueck et al.    | 2013 | CAG Iopromide                        | 104 versus 208     | Ascorbic acid 500 mg IV at 24 hours and 1 hour before | (1) NAC 600 mg iv at 24 hours and 1 hour before and (2) Placebo | NSS 1 mL/kg/h 12 hours before and 12 hours after | \( \uparrow \text{Cr} \geq 0.5/3 \text{days} \) | 43.0 versus 40.2 | 42.0 | \( 24.5 \text{ versus } 27.6 \text{ versus } 32.1 \) | 0.11* 0.20** 0 versus 0 versus 0 |

\( P \) value of * ascorbic acid and ** NAC compared to placebo group.

bid: twice daily; CAG: coronary angiography; CI-AKI: contrast-induced acute kidney injury; Cr: creatinine; g: gram; h: hour; IONICM: isoosmolarity nonionic contrast media; IV: intravenous; kg: kilogram body weight; LONICM: low osmolarity nonionic contrast media; mg: milligram; mL: milliliter; NAC: N-acetylcysteine; ND: no data; NSS: normal saline solution; N/2: 0.45% NaCl po: per oral route; q12h: every 12 hours; RRT: renal replacement therapy.
the CI-AKI. Recently, Brueck et al. [92] prospectively randomized 520 patients who were undergoing CAG into 3 groups to receive (1) ascorbic acid 500 mg 24 h and 1 h before procedure, (2) NAC 600 mg 24 h and 1 h before procedure, and (3) placebo. All patients received intravenous 0.9% NaCl at a rate of 1 mL/kgBW/h from 12 h before to 12 h after the procedure. The incidences of CI-AKI were not significantly different. Due to the conflicting results of ascorbic acid in preventing CI-AKI in at risk patients, the use of ascorbic acid for CI-AKI prophylaxis is deniable.

2.11. Tocopherol (Vitamin E) for CI-AKI Prevention. Tocopherol has been widely studied on its antioxidant property [84, 86], while using this agent for CI-AKI prophylaxis might be theoretically possible. A recent experimental study by Kongkham et al. on alpha tocopherol showed the renoprotective effect on the CI-AKI rat model by attenuating renal damage through antioxidant capacity.

The clinical trials on efficacy of using tocopherol for CI-AKI prophylaxis are summarized in Table 6. The first clinical trial in 2009 of Tasanarong et al. [93] randomized 103 patients who were undergoing coronary angiography to receive oral alpha tocopherol 525 IU once daily for 2 days before and on the day of procedure or placebo. All patients received intravenous 0.9% NaCl 1 mL/kgBW/h for 12 h before and 12 h after the angiography. Compared to placebo group, the incidence of CI-AKI was significantly lower in tocopherol group: 5.88 versus 23.08% (P = 0.02). In 2013, Tasanarong et al. [94] published a larger trial which enrolled 305 patients to ensure the positivity of the results. The patients who were undergoing elective coronary angiography were prospectively randomized into 3 groups to receive (1) alpha tocopherol 350 mg per day, (2) gamma tocopherol 300 mg per day, or (3) placebo. The prescribed regimen was initiated 5 days before and continued for 2 days after the angiography. All patients received intravenous 0.9% NaCl at a rate of 1 mL/kgBW/h for 12 h before and 12 h after the angiography. The incidences of CI-AKI were lower in both groups of patients who receive tocopherol treatment: 4.9, 5.9, and 14.9%, respectively (P = 0.02).

In contrast, a smaller study by Kitzler et al. [95] showed a negative result. Thirty patients who were undergoing computed tomography with nonionic contrast media were randomized to receive oral alpha tocopherol 300 mg per day, or placebo. The prescribed regimen was initiated 5 days before and continued for 2 days after the angiography. The incidences of CI-AKI were lower in both groups of patients who receive tocopherol treatment: 4.9, 5.9, and 14.9%, respectively (P = 0.02). As a result of limited and inconsistent evidence of dopamine for CI-AKI prophylaxis and possibility of adverse outcome in patients who received dopamine treatment, the dopamine treatment for CI-AKI prophylaxis remains undesirable.

2.13. Fenoldopam for CI-AKI Prevention. Fenoldopam is a selective dopamine A1 receptor agonist and hypothetically increases renal blood flow in a similar manner to dopamine. This effect might be beneficial in the prevention of CI-AKI.

The clinical trials of fenoldopam use for CI-AKI prophylaxis are summarized in Table 8. In the first clinical trial [103], the patients were randomized to receive 0.45% NaCl alone or with fenoldopam or NAC. The incidences of CI-AKI were similar: 15.3, 15.7, and 17.7%, respectively (P = 0.919). Stone et al. [104] conducted a larger prospective trial comparing patients who received fenoldopam in conjunction with 0.45% NaCl or 0.45% NaCl alone. There was no difference in CI-AKI incidence: 33.6 versus 30.1%, respectively (P = 0.61). Ng et al. [105] compared the patients who received intravascular volume expansion protocol with fenoldopam or NAC. There was no difference in the incidence of CI-AKI: 20% versus 11.4%, respectively (P = 0.4). Moreover, the administration of fenoldopam resulted in decrease in blood pressure and increase in heart rate [104] which might be potentially harmful to the patients. In summary, all available evidence showed the negative results and undesirable side effect. Hence, the prophylactic use of fenoldopam for CI-AKI is disagreeable.
### Table 6: Prospective, randomized clinical trials comparing efficacy of vitamin E with placebo and other agents for contrast-induced AKI after angiography prophylaxis.

| Authors               | Year | Type of procedure and contrast media | Number of patients | Study protocol | Intravascular volume expansion and NAC protocol | CI-AKI definition | Mean GFR Intervention versus control (mL/min/1.73 m²) | Incidence of CI-AKI Intervention versus control (%) | P value | Incidence of CI-AKI Control versus control (%) | RRT requirement Intervention versus control (%) |
|-----------------------|------|-------------------------------------|--------------------|----------------|-----------------------------------------------|-------------------|-------------------------------------------------|--------------------------------------------------|---------|-----------------------------------------------|-----------------------------------------------|
| Tasanarong et al. [93] | 2009 | CAG Iopromide                        | 51 versus 52       | Alpha tocopherol 525 IU po OD for 2 days before | Placebo           | NSS 1 mL/kg/h 12 hours before and after | ↑Cr ≥ 25%/2 days or ↑Cr ≥ 0.5/2 days                                 | 41 versus 42 | 5.88 versus 23.08 | 0.02                                           | 0 versus 0                                  |
| Tasanarong et al. [94] | 2013 | CAG Iopromide                        | 102 versus 101     | Po 5 days before and 2 days after of (1) α -tocopherol 350 mg/d (2) γ -tocopherol 300 mg/d | Placebo           | NSS 1 mL/kg/h 12 hours before and after | ↑Cr ≥ 25%/2 days or ↑Cr ≥ 0.5/2 days                                 | 45 versus 46 | 4.9 versus 5.9 | 0.02                                           | 0 versus 0                                  |
| Kitzler et al. [95]   | 2012 | CT Iopromide                         | 10 versus 10       | Vitamin E emulsion 540 mg IV every 6 hours 12 hours before and after | N/21 mL/kg/h 12 hours before and after plus placebo (2) Placebo | ↑Cr ≥ 25%/2 days | 64 versus 63                                    | 0 versus 0                                      | NS      | ND                                            |                                               |

CAG: coronary angiography; CI-AKI: contrast-induced acute kidney injury; Cr: creatinine; CysC: cystatin C; CT: computed tomography; d: day; h: hour; IV: intravenous; kg: kilogram body weight; mg: milligram; mL: milliliter; NAC: N-acetylcysteine; ND: no data; N/2: 0.45% NaCl; OD: once daily; po: per oral route; q12h: every 12 hours; RRT: renal replacement therapy.
Table 7: Prospective, randomized clinical trials comparing efficacy of dopamine with placebo and other agents for contrast-induced AKI after angiography prophylaxis.

| Authors        | Year | Type of procedure and contrast media | Number of patients | Intervention versus control | Study protocol | Intravascular volume expansion and NAC protocol | CI-AKI definition | Mean GFR Intervention versus control (mL/min/1.73 m²) | Incidence of CI-AKI Intervention versus control (%) | P value | RRT requirement Intervention versus control (%) |
|----------------|------|--------------------------------------|--------------------|----------------------------|----------------|-----------------------------------------------|------------------|-----------------------------------------------------|---------------------------------------------------|---------|----------------------|
| Hans et al.    | 1998 | PAG, Iohexol                          | 28 versus 27       | Dopamine 2.5 mcg/kg/h 1 hour before and 11 hours after | NSS None       | ↑Cr ≥0.5/2 days                               | 42.18 versus 48.8 | 71 versus 28.6                                      | 0.026 ND                                           |
| Kapoor et al.  | 1996 | CAG, Urograffin                       | 20 versus 20       | Dopamine 5 mcg/kg/h 30 minutes before and 6–8 hours after | None None      | ↑Cr ≥25%/1 day, ↑Cr ≥25%/3 days                | *Cr 1.50 versus 1.52 | 0 versus 50 ND                                      | 0 versus 0                                           |
| Abizaid et al. | 1999 | CAG, Hexabrix                         | 20 versus 20       | Dopamine 2.5 mcg/kg/h (1) None, Aminophylline IV 4 mg/kg then 0.4 mg/kg/h, N/2 21 mL/kg/h 12 hours before and after | (2) None       | ↑Cr ≥25%/2 days                               | *Cr 1.9 versus 2.3 versus 1.9 | 50 versus 30,35,35 | 0.60 0 versus 5 versus 5 |
| Stevens et al. | 1999 | CAG, ND                               | 22 versus 21       | Dopamine 3 mcg/kg/h, Furosemide 1 mg/kg IV before, and Mannitol 12.5g in D5W 250 mL IV in 2 hours (1) Dopamine 3 mcg/kg/h and Furosemide 1 mg/kg IV before (2) None, Mannitol 12.5g, N/2 21 mL/kg/h 6 hours after then adjust to match urine output | None           | ↑Cr ≥25%/0.5–2 days                           | 33.73 versus 31.44 versus 30.48 | 31.8 versus 33.3 versus 30.9 | 0.98 4.5 versus 4.8 versus 9.1 |

*Mean GFR data is not available. Data is shown as mean serum creatinine in mg/dL.
CAG: coronary angiography; CI-AKI: contrast-induced acute kidney injury; Cr: creatinine; g: gram; D5W: 5% dextrose solution; h: hour; IV: intravenous; kg: kilogram body weight; mcg: microgram; mg: milligram; mL: milliliter; NAC: N-acetylcysteine; ND: no data; N/2: 0.45% NaCl; PAG: peripheral angiography; po: per oral route; q12h: every 12 hours; RRT: renal replacement therapy.
| Authors          | Year | Type of procedure and contrast media | Number of patients | Study protocol | Intravascular volume expansion and NAC protocol | CI-AKI definition | Mean GFR Intervention versus control (mL/min/1.73 m²) | Incidence of CI-AKI Intervention versus control (%) | P value | RRT requirement Intervention versus control (%) |
|------------------|------|-------------------------------------|-------------------|----------------|-----------------------------------------------|-------------------|----------------------------------------------------|-------------------------------------------------|---------|-------------------------------------------------|
| Allaqab and et al. [103] | 2002 | CAG IONICM                          | 38 versus 40      | Fenoldopam 0.1 mcg/kg/h IV 4 hours before and after (1) None | N/2 1 mL/kg/h 12 hours before and after | ↑Cr ≥0.5/2 days | 35.5 versus 34.1 versus 36.9 | 15.7 versus 15.3 versus 17.7 | 0.919    | **Total 1.62                                      |
| Stone et al. [104] | 2003 | CAG ND                              | 157 versus 158    | Fenoldopam 0.05–0.1 mcg/kg/h IV 1 hour before and 12 hours after Placebo | N/2 1.5 mL/kg/h 2–12 hours before (1 mL/kg/h if CHF) | ↑Cr ≥25%/1–4 days | 29.0 versus 29.1 | 33.6 versus 30.1 | 0.61     | 2.6 versus 1.9                                  |
| Ng et al. [105]   | 2006 | CAG IONICM and IONICM               | 47 versus 48      | Fenoldopam 0.1 mcg/kg/h IV 1–2 hours before and 6 hours after NAC 600 mg po bid NSS or D5W 1 mL/kg/h 1–2 hours before and 6–12 hours after | | ↑Cr ≥25%/1–3 days or ↑Cr ≥0.5/1–3 days | * Cr 1.53 versus 1.46 | 20.0 versus 11.4 | ND       |                                                 |

*Mean GFR data is not available. Data is shown as mean serum creatinine in mg/dL.

**Percentage of RRT requirement data in each group is not available. Data is shown as percentage of RRT requirement in all patients.

bid: twice daily; CAG: coronary angiography; CHF: congestive heart failure; CI-AKI: contrast-induced acute kidney injury; Cr: creatinine; g: gram; D5W: 5% dextrose solution; h: hour; IONICM: iso-osmolarity nonionic contrast media; IV: intravenous; kg: kilogram body weight; IONICM: low osmolarity nonionic contrast media; mcg: microgram; mg: milligram; mL: milliliter; NAC: N-acetylcysteine; ND: no data; NSS: normal saline solution; N/2: 0.45% NaCl; po: per oral route; q12h: every 12 hours; RRT: renal replacement therapy.
2.14. Theophylline for CI-AKI Prevention. In general, adenosine is an intrarenal vasoconstrictor and a mediator of the tubuloglomerular feedback mechanism. Theophylline, an adenosine antagonist, was logical to evaluate for risk reduction in CI-AKI. In animal model, the administration of contrast media resulted in an increased excretion of endogenous adenosine. Theophylline is an adenosine antagonist which might theoretically improve the renal hemodynamic in patients who receive contrast media. In experimental study, the decline of renal blood flow after contrast media administration was attenuated by theophylline [106].

The clinical trials of theophylline use for CI-AKI prophylaxis are summarized in Table 9. Two randomized studies by Huber et al. [107, 108] in 2002 and 2003 for evaluation the efficacy of theophylline versus placebo gave positive results. The incidence of CI-AKI was lower in the patients who receive theophylline. The more recent randomized studies also compared the efficacy of theophylline with saline, NAC with saline, and saline alone [109–112]. The incidence of CI-AKI was lower in theophylline group compared to saline group. Moreover, these studies showed comparable [109, 111] or even more preferable [110, 112] results of theophylline than NAC. However, Abizaid et al. [101] randomized 60 patients into 3 groups: (1) aminophylline with saline, (2) saline alone, and (3) dopamine with saline. The incidences of CI-AKI were similar: 35, 30, and 30%, respectively (P = 0.6). However, the requirement of RRT was slightly higher among the patients who received aminophylline with saline compared to others: 5 versus 0%.

Ix et al. [113] performed a meta-analysis including 7 trials with 480 patients and showed that mean change of SCr was lower in theophylline and aminophylline pretreatment group (P = 0.004). In 2012, Dai et al. [114] conducted a meta-analysis to determine the efficiency of theophylline in CI-AKI prevention. Sixteen trials with 1,412 patients were included. The study showed that theophylline significantly reduced the risk of CI-AKI (RR: 0.48, 95% CI: 0.26–0.89; P = 0.02). In contrast, Bagshaw and Ghali [115] published systematic review and meta-analysis and showed that pretreatment with theophylline had a trend toward reduction in CI-AKI incidence (RR: 0.40, 95% CI: 0.14–1.16; P = 0.09). Meta-analysis by Kelly et al. [58] with 531 patients from 6 trials showed a nonsignificant protective trend of theophylline for CI-AKI prevention (RR: 0.49, 95% CI: 0.23–1.06).

Due to inconsistent efficacy of theophylline across studies, the use of theophylline for CI-AKI prevention is not suggested.

2.15. Nebivolol for CI-AKI Prevention. Nebivolol is a β1-receptor antagonist which has vasodilatory and antioxidant effect [116, 117]. After contrast media administration, the pretreated rats with nebivolol had less oxidative stress marker and histological abnormalities compared to those without nebivolol pretreatment [118].

Table 10 shows the details of clinical trials of nebivolol for CI-AKI prophylaxis. In 2011, Avci et al. [119] prospectively randomized 90 patients undergoing coronary angiogram to receive nebivolol 5 mg once daily with saline or metoprolol 50 mg once daily with saline. The incidence of CI-AKI was significantly lower in nebivolol group: 24 versus 33% (P = 0.039), respectively. Günebakmaz et al. [120] randomized 120 patients who were undergoing coronary angiography into 3 groups: (1) nebivolol 5 mg once daily with saline, (2) saline alone, and (3) NAC with saline. The incidence of CI-AKI was numerically lower in nebivolol group: 20, 27.5, and 22.5% (P = 0.72), respectively. In behalf of scanty studies in human, the use of nebivolol for CI-AKI prophylaxis is discouraged.

2.16. Atrial Natriuretic Peptide for CI-AKI Prevention. Atrial natriuretic peptide (ANP) is a potent endogenous natriuretic compound produced by cardiac myocytes in right atrium. In rat model, ANP infusion results in augmentation of glomerular filtration rate predominantly by a hemodynamic mechanism [121]. ANP treatment showed to ameliorate ischemic AKI in rat [122] and prevent CI-AKI in heart failure induced dogs [123].

Kurnik et al. [124] randomized 247 patients with CKD who were undergoing radiographic procedures which required contrast media administration to receive intravenous 0.45% saline for 12 h before and after the procedure or a combination of saline and one among three different rates of ANP infusion (0.01 µg/kg/min, 0.05 µg/kg/min, or 0.1 µg/kg/min) for 30 min before and continuing for 30 min after the procedure. The incidences of CI-AKI were not different between 4 groups of patients. Morikawa et al. [125] randomized 254 patients with CKD who were undergoing coronary angiography to receive either ANP intravenous infusion at a rate of 0.042 µg/kg/min or intravenous ringer solution alone at a rate of 1.3 mL/kg/h before and after the administration of contrast media. The incidences of CI-AKI were significantly lower in the ANP treatment group than in control group: 3.2 and 11.7%, respectively (P = 0.015). At 1 month, the incidences of an increase in SCr of ≥25% or ≥0.5 mg/dL from baseline were also significantly lower in ANP-treated group than in the control group: 2.4 and 12.5%, respectively (P = 0.006). Due to sparse in number of evidences and inconsistent efficacies of ANP across the studies, the use of ANP for CI-AKI prevention is not indicative.

2.17. Prostaglandins for CI-AKI Prevention. Prostaglandins (PG) arise from enzymatic metabolism of arachidonic acid, which appeared in various parts of the kidney and had an effect on controlling renal blood flow and glomerular filtration rate [126]. In animal model, the vasodilatory effect of PG had an important role in maintaining blood flow to the poorly oxygenated region of the kidney [127], which directly counteracts the renal vasoconstrictive effect after the contrast media administration. Besides, an inhibition of PG synthesis in rats appeared to aggravate the renal injury from contrast media administration [16]. The infusion of PG had protective effects on renal function in either ischemia-reperfusion injury or contrast media administration model [128–130].

Gurkowski et al. [131] randomized 125 patients who were undergoing a radiologic contrast procedure to receive
Table 9: Clinical trials comparing theophylline with placebo and other agents for prophylaxis of contrast-induced AKI after angiography.

| Authors            | Year | Type of procedure and contrast media | Number of patients | Intervention versus control | Study protocol | Intravenous volume expansion and NAC protocol | CI-AKI definition | Mean GFR Intervention versus control (mL/min/1.73 m²) | Incidence of CI-AKI Intervention versus control (%) | RRT requirement Intervention versus control (%) |
|--------------------|------|-------------------------------------|--------------------|-----------------------------|----------------|-----------------------------------------------|------------------|------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Huber et al. [107] | 2002 | CAG/PAG lomeprol                    | 50 versus 50       | Theophylline 200 mg IV 30 minutes before | Placebo        | ND                                            | ↑Cr ≥0.5/2 days | *Cr 2.07 versus 1.92                           | 4 versus 16                                      | 0.042                                           |
| Huber et al. [108] | 2003 | CAG Imeron                          | 50 versus 50       | Theophylline 200 mg IV 30 minutes before | Placebo        | ND                                            | ↑Cr ≥0.5/2 days | *Cr 1.65 versus 1.72                           | 4 versus 20                                      | 0.0138                                          |
| Dussol et al. [33] | 2006 | Various procedures (lomeprol, iohexol, and iopromide) | 80 versus 76 versus 77 versus 79 | Theophylline 5 mg/kg 1 hour before | ND             | ↑Cr ≥2/2 days or ↑Cr ≥0.5/2 days               | 33 versus 38   | 3.3 versus 33 versus 3.2 versus 3.4         | ND                                               | 0 versus 0 versus 0                             |
| Huber et al. [109] | 2006 | Various procedures (Imeron)         | 51 versus 50 versus 19 | Theophylline 200 mg IV 30 minutes before | (1) NAC 600 mg IV bid (2) Combination | According to underlying disease | ↑Cr ≥0.5/2 days | *Cr 1.25 versus 1.25 versus 1.28               | 2 versus 12 versus 4                             | 0.047                                           |
| Baskurt et al. [110] | 2009 | CAG Ioversol                        | 72 versus 72 versus 73 | Theophylline 200 mg NAC 600 mg po bid | None           | NSS1 mL/kg/h 12 hours before and after | ↑Cr ≥0.5/2 days | *Cr 1.47 versus 1.3 versus 1.39              | 0 versus 6.9 versus 9.6                         | 0.033                                           |
| Kimbara et al. [111] | 2010 | CAG iopamidol                      | 15 versus 15       | Theophylline 250 mg IV 30 minutes before | (1) None (2) NAC 704 mg po bid | NSS1 mL/kg/h 12 hours before and after | ↑Cr ≥0.5/2 days | 63.4 versus 63.7 versus 62.4                 | 0 versus 26.7 versus 0                           | 0.009                                           |
| Bilasy et al. [112] | 2012 | CAG iopamidol                      | 30 versus 30       | Theophylline 200 mg in NSS100 mL IV 30 minutes before and NAC 600 mg po bid | Placebo and NAC 600 mg po bid | NSS1 mL/kg/h 12 hours before and after (In case of CHF NSS 0.5 mL/kg/h) | ↑Cr ≥0.5/3 days or ↑Cr ≥0.5/3 days | 58.6 versus 61.8                              | 0 versus 20                                      | 0.01                                           |
| Abizaid et al. [101] | 1999 | CAG Hexabrix                        | 20 versus 20       | Aminophylline 4 mg/kg then 0.4 mg/kg/h 2 hours before | None           | NSS1 mL/kg/h 12 hours before and after         | ↑Cr ≥0.5/3 days | *Cr 1.9 versus 2.3 versus 2.1                 | 35 versus 30 versus 50                          | 0.60                                            |

*Mean GFR data is not available. Data is shown as mean serum creatinine in mg/dL.*

**P value of intervention group compare to combination group.

bid: twice daily; CAG: coronary angiography; CHF: congestive heart failure; CI-AKI: contrast-induced acute kidney injury; Cr: creatinine; g: gram; D5W: 5% dextrose solution; h: hour; IV: intravenous; kg: kilogram body weight; mg: milligram; mL: milliliter; NAC: N-acetylcysteine; ND: no data; NSS: normal saline solution; N/2: 0.45% NaCl; po: per oral route; q12h: every 12 hours; RRT: renal replacement therapy.
**Table 10: Clinical trials comparing nebivolol with placebo and other agents for prophylaxis of contrast-induced AKI after angiography.**

| Authors          | Year | Type of procedure and contrast media | Number of patients Intervention versus control | Study protocol Intervention | Control | Intravascular volume expansion and NAC protocol | CI-AKI definition | Mean GFR Intervention versus control (mL/min/1.73 m²) | Incidence of CI-AKI Intervention versus control (%) | Incidence of CI-AKI Control (%) | RRT requirement Intervention versus control (%) |
|------------------|------|--------------------------------------|------------------------------------------------|----------------------------|---------|-----------------------------------------------|------------------|------------------------------------------------|---------------------------------|--------------------------------|---------------------------------|
| Avci et al. [119] 2011 | CAG Ioxaglate | 55 versus 35 | Nebivolol 5 mg po OD 1 week before to 2 days after | Metoprolol 50 mg week before to 2 days after | NSS 1 mL/kg/h 12 hours before and 24 hours after | ↑Cr ≥25%/2 days | 44.75 versus 43.27 | 24 versus 33 | 0.039 | ND |
| Günebakmaz et al. [120] 2012 | CAG Iopramide | 40 versus 40 | Nebivolol 5 mg po OD 1 day before and after | (1) None (2) NAC 600 mg po bid | NSS 1 mL/kg/h 6 hours before and 12 hours after | ↑Cr ≥25%/2 or 5 days or ↑Cr ≥0.5/2 or 5 days | 51.6 versus 47.6 versus 49.8 | 20 versus 27.5 versus 22.5 | 0.72 | ND |

*Number of patient data in each group is not available. Data is shown as total patients in both groups.

**Incidence of CI-AKI for intervention group data is not available. Data is shown as percentage incidence of CI-AKI decrease compared to control group.

CAG: coronary angiography; CHF: congestive heart failure; CI-AKI: contrast-induced acute kidney injury; Cr: creatinine; g: gram; D5W: 5% dextrose solution; h: hour; IV: intravenous; kg: kilogram body weight; mcg: microgram; mg: milligram; mL: milliliter; NAC: N-acetylcysteine; ND: no data; NSS: normal saline solution; N/2: 0.45% NaCl; po: per oral route; q12h: every 12 hours; RRT: renal replacement therapy; tid: thrice daily.
misoprostol, a synthetic PGE₉ analogue, 200 mg 4 times a day for 3 days before and 2 days after the procedure or a placebo. Misoprostol treatment showed to significantly attenuate the reduction of creatinine clearance. Sparaggis et al. [132] randomized 208 patients with CKD who were undergoing coronary angiography to receive iloprost, a synthetic analogue of PGI₂, 1 ng/kg/min for 30–90 minutes before and 4 h after the procedure or placebo. The incidences of CI-AKI were lower in iloprost group than in control group: 8 and 22%, respectively (P = 0.005). Despite the positive results of the studies using PG analogue for CI-AKI prophylaxis, the sparse number of studies causes a reluctance in using it. Further studies are needed to prove the efficacy of PG analogue for CI-AKI prophylaxis.

3. Conclusion

CI-AKI is a common condition that is associated with increased morbidity and mortality, particularly in high risk patients. Volume expansion and treatment of dehydration are established interventions in the prevention of CI-AKI. Oral volume expansion has demonstrated some benefit, but there is not enough evidence to show that it is as effective as intravenous volume expansion. However, only intravascular volume expansion with isotonic saline solution or sodium bicarbonate is regarded as the only effective therapy and is recommended in the prevention of CI-AKI depending on the patient's volume status assessment. For isotonic saline administration, most studies suggest that 0.9% saline should be started at a rate ≥ 1–1.5 mL/kg/h 3–12 h before and 6–12 h after contrast media exposure. Instead of sodium bicarbonate administration, most studies suggest that sodium bicarbonate should be started at a rate of 3 mL/kg/h 1 h before and 1 mL/kg/h 6 h after contrast media exposure.

There are varieties of pharmacological interventions for CI-AKI prophylaxis that has been developed in many experimental studies and clinical trials. Based on the evidence tables and even taking the most recent study, there are no currently approved pharmacologic agents for the prevention of CI-AKI. Overall evidence of NAC is not consistent or overwhelming, but oral NAC has a low risk of adverse events and usually a low cost. We suggest using oral NAC combined with standard intravenous volume expansion in patients with increased risk of CI-AKI. Recent clinical trials for early high-dose or short-term statin demonstrated the benefit for preventing CI-AKI. In the future, large, well-designed, and adequately powered randomized clinical trials are urgently needed to study this important issue. Other agents, theophylline, nebulol, prostaglandin, ANP, dopamine, and fenoldopam, showed some benefit reports, but the majority of evidence showed conflicting results and some therapies were even harmful. In addition, the novel pharmacological strategies such as ascorbic acid and tocopherol are required to prove their benefit in preventing CI-AKI in the future.

Future approaches include large plan excellent clinical trials of oral or intravenous antioxidants, vasodilators, or novel pharmacologic agents combined with intravenous volume expansion to decrease the incidence of CI-AKI. Newer criteria for early diagnosis of CI-AKI by rising SCr, changing urine output, and/or novel biomarker need to be developed and used to be the standard criteria for general practices.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] A. S. Berns, “Nephrotoxicity of contrast media,” *Kidney International*, vol. 36, no. 4, pp. 730–740, 1989.
[2] M. R. Rudnick, S. Goldfarb, and J. Tumlin, “Contrast-induced nephropathy: is the picture any clearer?” *Clinical Journal of the American Society of Nephrology*, vol. 3, no. 1, pp. 261–262, 2008.
[3] ACT Investigators, “Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT),” *Circulation*, vol. 124, no. 11, pp. 1250–1259, 2011.
[4] H. S. Gurm, D. E. Smith, O. Berwanger et al., “Contemporary use and effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy among patients undergoing percutaneous coronary intervention,” *Journal of the American College of Cardiology*, vol. 5, no. 1, pp. 98–104, 2012.
[5] M. Tepel, P. Aspelin, and N. Lameire, “Contrast-induced nephropathy: a clinical and evidence-based approach,” *Circulation*, vol. 113, no. 14, pp. 1799–1806, 2006.
[6] I. Goldenberg and S. Matetzky, “Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies,” *CMAJ*, vol. 172, no. 11, pp. 1461–1471, 2005.
[7] S. Fishbane, J. H. Durham, K. Marzo, and M. Rudnick, “N-acetylcysteine in the prevention of radiocontrast-induced nephropathy,” *Journal of the American Society of Nephrology*, vol. 15, no. 2, pp. 251–260, 2004.
[8] T. G. Gleeson and S. Bulugahapitiya, “Contrast-induced nephropathy,” *The American Journal of Roentgenology*, vol. 183, no. 6, pp. 1673–1689, 2004.
[9] M. Maeder, M. Klein, T. Fehr, and H. Rickli, “Contrast nephropathy: review focusing on prevention,” *Journal of the American College of Cardiology*, vol. 44, no. 9, pp. 1763–1771, 2004.
[10] S. W. Murphy, B. J. Barrett, and P. S. Parfrey, “Contrast nephropathy,” *Journal of the American Society of Nephrology*, vol. 11, no. 1, pp. 177–182, 2000.
[11] H. S. Thomsen and S. K. Morcos, “Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines,” *British Journal of Radiology*, vol. 76, no. 908, pp. 513–518, 2003.
[12] A. S. Gami and V. D. Garovic, “Contrast nephropathy after coronary angiography,” *Mayo Clinic Proceedings*, vol. 79, no. 2, pp. 201–219, 2004.
[13] M. R. Rudnick, S. Goldfarb, L. Wexler et al., “Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The lohexol cooperative study,” *Kidney International*, vol. 47, no. 1, pp. 254–261, 1995.
[14] B. R. C. Kurnik, L. S. Weisberg, I. M. Cuttler, and P. B. Kurnik, “Effects of atrial natriuretic peptide versus mannitol on renal blood flow during radiocontrast infusion in chronic renal failure,” *Journal of Laboratory and Clinical Medicine*, vol. 116, no. 1, pp. 27–35, 1990.
controlled study,” *The American Heart Journal*, vol. 155, no. 3, pp. 499–e1, 2008.

[75] H. Özhan, I. Erden, S. Ordu et al., “Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography,” *Angiology*, vol. 61, no. 7, pp. 711–714, 2010.

[76] A. Tosio, M. Maioli, M. Leoncini et al., “Usefulness of Atorvastatin (80 mg) in Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Disease,” *The American Journal of Cardiology*, vol. 105, no. 3, pp. 288–292, 2010.

[77] G. Patti, E. Ricottini, A. Nusca et al., “Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial),” *The American Journal of Cardiology*, vol. 108, no. 1, pp. 1–7, 2011.

[78] C. Quintavalle, D. Fiore, F. de Micco et al., “Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury,” *Circulation*, vol. 126, no. 25, pp. 3008–3016, 2012.

[79] Y. Han, G. Zhu, L. Han et al., “Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease,” *Journal of the American College of Cardiology*, vol. 63, no. 1, pp. 62–70, 2014.

[80] M. Leoncini, A. Tosio, M. Maioli, F. Tropeano, S. Villani, and F. Bellandi, “Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome. Results from protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS study),” *Journal of the American College of Cardiology*, vol. 63, no. 1, pp. 71–79, 2014.

[81] B.-C. Zhang, W.-M. Li, and Y.-W. Xu, “High-dose statin pre-treatment for the prevention of contrast-induced nephropathy: a meta-analysis,” *Canadian Journal of Cardiology*, vol. 27, no. 6, pp. 851–858, 2011.

[82] Y. Zhou, W. J. Yuan, N. Zhu, and L. Wang, “Short-term, high-dose statins in the prevention of contrast-induced nephropathy: a systematic review and meta-analysis,” *Clinical Nephrology*, vol. 76, no. 6, pp. 475–483, 2011.

[83] T. Zhang, L.-H. Shen, L.-H. Hu, and B. He, “Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis,” *The American Journal of Nephrology*, vol. 33, no. 4, pp. 344–351, 2011.

[84] I. Durak, H. Özbek, M. Karaayvaz, and H. S. Öztürk, “Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs: effects of antioxidant supplementation on the cisplatin nephrotoxicity,” *Drug and Chemical Toxicology*, vol. 25, no. 1, pp. 1–8, 2002.

[85] N. Lloberas, J. Torras, I. Herrero-Fresneda et al., “Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxidant treatment,” *The FASEB Journal*, vol. 16, no. 8, pp. 908–910, 2002.

[86] B. H. Ali, “Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research,” *Food and Chemical Toxicology*, vol. 41, no. 11, pp. 1447–1452, 2003.

[87] P. A. McCullough, R. Wolyn, L. L. Rocher, R. N. Levin, and W. W. O’Neill, “Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality,” *The American Journal of Medicine*, vol. 103, no. 5, pp. 368–375, 1997.

[88] K. Spargias, E. Alexopoulos, S. Kyrozopoulos et al., “Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention,” *Circulation*, vol. 110, no. 18, pp. 2837–2842, 2004.

[89] A. Boscheri, C. Weinbrenner, B. Botzek, K. Reynen, E. Kuhlisch, and R. H. Strasser, “Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction,” *Clinical Nephrology*, vol. 68, no. 5, pp. 279–286, 2007.

[90] S.-H. Jo, B.-K. Koo, J.-S. Park et al., “N-acetylcysteine versus AScobic acid for preventing contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography. NASPI study—a prospective randomized controlled trial,” *The American Heart Journal*, vol. 157, no. 3, pp. 576–583, 2009.

[91] L. Zhou and H. Chen, “Prevention of contrast-induced nephropathy with ascorbic acid,” *Internal Medicine*, vol. 51, no. 6, pp. 531–535, 2012.

[92] M. Brueck, H. Cengiz, R. Hoeltgen et al., “Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial,” *Journal of Invasive Cardiology*, vol. 25, no. 6, pp. 276–283, 2013.

[93] A. Tasanarong, D. Piyayotai, and S. Thitiarchakul, “Protection of radiocontrast induced nephropathy by vitamin E (alpha tocopherol): a randomized controlled pilot study,” *Journal of the Medical Association of Thailand*, vol. 92, no. 10, pp. 1273–1281, 2009.

[94] A. Tasanarong, A. Vohakiat, P. Hutyanon, and D. Piyayotai, “New strategy of alpha- and gamma-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures,” *Nephrology Dialysis Transplantation*, vol. 28, no. 2, pp. 337–344, 2013.

[95] T. M. Kitzler, A. Jaberi, G. Sendihofer et al., “Efficacy of vitamin E and N-acetylcysteine in the prevention of contrast induced kidney injury in patients with chronic kidney disease: a double blind, randomized controlled trial,” *Wiener Klinische Wochenschrift*, vol. 124, no. 9–10, pp. 312–319, 2012.

[96] R. J. Workman, M. I. Shaff, R. V. Jackson, D. Jiggs, M. G. Frazer, and C. Briscoe, “Relationship of renal hemodynamic and functional changes following intravascular contrast to the renin-angiotensin system and renal prostacyclin in the dog,” *Investigative Radiology*, vol. 18, no. 2, pp. 160–166, 1983.

[97] S. N. Heyman, M. Brezis, F. H. Epstein, K. Spokes, P. Silva, and S. Rosen, “Early renal medullary hypoxic injury from radiocontrast and indomethacin,” *Kidney International*, vol. 40, no. 4, pp. 632–642, 1991.

[98] U. Elkayam, T. M. H. Ng, P. Hatamizadeh, M. JamMohamed, and A. Mehra, “Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action,” *Circulation*, vol. 117, no. 2, pp. 200–205, 2008.

[99] A. Kapoor, N. Sinha, R. K. Sharma et al., “Use of dopamine in prevention of contrast induced acute renal failure—a randomised study,” *International Journal of Cardiology*, vol. 53, no. 3, pp. 233–236, 1996.

[100] S. S. Hans, B. A. Hans, R. Dhillon, C. Dmuchowski, and J. Glover, “Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency,” *The American Surgeon*, vol. 64, no. 5, pp. 432–436, 1998.

[101] A. S. Abizaid, C. E. Clark, G. S. Mintz et al., “Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency,” *The American Journal of Cardiology*, vol. 83, no. 2, pp. 260–263, 1999.
[102] M. A. Stevens, P. A. McCullough, K. J. Tobin et al., “A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. study. Prevention of radiocontrast induced nephropathy clinical evaluation,” Journal of the American College of Cardiology, vol. 33, no. 2, pp. 403–411, 1999.

[103] S. Allaqaband, R. Tumlin et al., “Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy,” Catheterization and Cardiovascular Interventions, vol. 57, no. 3, pp. 279–283, 2002.

[104] G. W. Stone, P. A. McCullough, J. A. Tumlin et al., “Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial,” Journal of the American Medical Association, vol. 290, no. 17, pp. 2284–2291, 2003.

[105] T. M. H. Ng, S. W. Shurmur, M. Silver et al., “Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFACIN),” International Journal of Cardiology, vol. 109, no. 3, pp. 322–328, 2006.

[106] L. J. Arend, G. L. Bakris, J. C. Burnett Jr., C. Megerian, and W. S. Spielman, “Role for intrarenal adenosine in the renal hemodynamic response to contrast media,” Journal of Laboratory and Clinical Medicine, vol. 110, no. 4, pp. 406–411, 1987.

[107] W. Huber, K. Ilgmann, M. Page et al., “Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blind study,” Radiology, vol. 223, no. 3, pp. 772–779, 2002.

[108] W. Huber, C. Schipek, K. Ilgmann et al., “Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency,” The American Journal of Cardiology, vol. 91, no. 10, pp. 1157–1162, 2003.

[109] W. Huber, F. Eckel, M. Hennig et al., “Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study,” Radiology, vol. 239, no. 3, pp. 793–804, 2006.

[110] M. Baskurt, B. Okcun, O. Abaci et al., “N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy,” European Journal of Clinical Investigation, vol. 39, no. 9, pp. 793–799, 2009.

[111] T. Kimbara, T. Hayano, N. Ohtani, Y. Furutani, K. Moritani, and M. Matsuzaki, “Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy,” Journal of Cardiology, vol. 55, no. 2, pp. 174–179, 2010.

[112] M. E. Bilasy, M. A. Oraby, H. M. Ismail, and F. A. Maklady, “Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures,” Journal of Interventional Cardiology, vol. 25, no. 4, pp. 404–410, 2012.

[113] J. H. Ix, C. E. McCulloch, and G. M. Chertow, “Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis,” Nephrology Dialysis Transplantation, vol. 19, no. 11, pp. 2747–2753, 2004.

[114] B. Dai, Y. Liu, L. Fu, Y. Li, J. Zhang, and C. Mei, “Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials,” The American Journal of Kidney Diseases, vol. 60, no. 3, pp. 360–370, 2012.

[115] S. M. Bagshaw and W. A. Gali, “Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis,” Archives of Internal Medicine, vol. 165, no. 10, pp. 1087–1093, 2005.

[116] S. S. Sule and W. Frishman, “Nebivolol: new therapy update,” Cardiology in Review, vol. 14, no. 5, pp. 259–264, 2006.

[117] A. Veverka, D. S. Nuzum, and J. L. Jolly, “Nebivolol: a third-generation β-adrenergic blocker,” Annals of Pharmacotherapy, vol. 40, no. 7-8, pp. 1353–1360, 2006.

[118] O. Toprak, M. Cirit, M. Tanrisev et al., “Preventive effect of nebivolol on contrast-induced nephropathy in rats,” Nephrology Dialysis Transplantation, vol. 23, no. 3, pp. 853–859, 2008.

[119] E. Avci, M. Yesil, S. Bayata, N. Postaci, E. Arikatan, and M. Cirit, “The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction,” Anadolu Kardiyoloji Dergisi, vol. 11, no. 7, pp. 613–617, 2011.

[120] O. Günebakmaz, M. G. Kaya, F. Koc et al., “Does nebivolol prevent contrast-induced nephropathy in humans?” Clinical Cardiology, vol. 35, no. 4, pp. 250–254, 2012.

[121] C.-L. Huang, J. Lewicki, L. K. Johnson, and M. G. Cogan, “Renal mechanism of action of rat atrial natriuretic factor,” Journal of Clinical Investigation, vol. 75, no. 2, pp. 769–773, 1985.

[122] M. Nakamoto, J. I. Shapiro, P. F. Shanley, L. Chan, and R. W. Schrier, “In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure,” Journal of Clinical Investigation, vol. 80, no. 3, pp. 698–705, 1987.

[123] K. B. Margulies, L. J. McKinley, P. G. Caverio, and J. C. Burnett Jr., “Induction and prevention of radiocontrast-induced nephropathy in dogs with heart failure,” Kidney International, vol. 38, no. 6, pp. 1101–1108, 1990.

[124] B. R. C. Kurnik, R. L. Allgren, F. C. Center, R. J. Solomon, E. R. Bates, and L. S. Weisberg, “Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy,” The American Journal of Kidney Diseases, vol. 31, no. 4, pp. 674–680, 1998.

[125] S. Morikawa, T. Sone, H. Tsuboi et al., “Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide,” Journal of the American College of Cardiology, vol. 53, no. 12, pp. 1040–1046, 2009.

[126] R. C. Harris, “Physiologic and pathophysiologic roles of cyclooxygenase-2 in the kidney,” Transactions of the American Clinical and Climatological Association, vol. 124, pp. 139–151, 2013.

[127] D. Schlondorff, “Renal prostaglandin synthesis. Sites of production and specific actions of prostaglandins,” The American Journal of Medicine, vol. 81, no. 2B, pp. 1–11, 1986.

[128] W. Krause, P. Muschick, and U. Krüger, “Use of near-infrared reflection spectroscopy to study the effects of x-ray contrast media on renal tolerance in rats: effects of a prostacyclin analogue and of phosphodiesterase inhibitors,” Investigative Radiology, vol. 37, no. 12, pp. 698–705, 2002.

[129] M. S. Paller and J. C. Manivel, “Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect,” Kidney International, vol. 42, no. 6, pp. 1345–1354, 1992.

[130] D. Grekas, H. Kalekou, and A. Tourkantonis, “Effect of prostaglandin E2 (PGE2) in the prevention of acute renal failure in anesthetized dogs. In situ renal preservation,” Renal Failure, vol. 11, no. 1, pp. 27–31, 1989.

[131] L. Gurrkowsk, M. MacDougall, and T. Wiegmann, “Effects of misoprostol on contrast-induced renal dysfunction,” The American Journal of Therapeutics, vol. 2, no. 11, pp. 837–842, 1995.

[132] K. Spargias, E. Adreanides, E. Demerouti et al., “Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention,” Circulation, vol. 120, no. 18, pp. 1793–1799, 2009.
[133] F. Boccalandro, M. Amhad, R. W. Smalling, and S. Sdringola, "Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast," *Catheterization and Cardiovascular Interventions*, vol. 58, no. 3, pp. 336–341, 2003.

[134] V. O. Gomes, C. E. Poli de Figueredo, P. Caramori et al., "N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial," *Heart*, vol. 91, no. 6, pp. 774–778, 2005.

[135] E. E. Ozcan, S. Guneri, B. Akdeniz et al., "Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial," *The American Heart Journal*, vol. 154, no. 3, pp. 539–544, 2007.